24.26
Elanco Animal Health Inc stock is traded at $24.26, with a volume of 2.09M.
It is up +3.72% in the last 24 hours and up +21.73% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
See More
Previous Close:
$23.39
Open:
$23.845
24h Volume:
2.09M
Relative Volume:
0.34
Market Cap:
$12.12B
Revenue:
$4.89B
Net Income/Loss:
$-242.00M
P/E Ratio:
-49.61
EPS:
-0.489
Net Cash Flow:
$315.00M
1W Performance:
+0.87%
1M Performance:
+21.73%
6M Performance:
+9.82%
1Y Performance:
+82.00%
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ELAN
Elanco Animal Health Inc
|
24.26 | 11.68B | 4.89B | -242.00M | 315.00M | -0.489 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.61 | 48.72B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
8.9544 | 39.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.49 | 37.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
78.13 | 32.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
540.24 | 23.41B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Ventures Expands Animal Health Innovation Ecosystem - Kalkine Media
Veterinary API Manufacturing Market to Reach USD 18.48 Billion by 2035 as Animal Health Investments and Zoonotic Disease Prevention Accelerate – SNS Insider - GlobeNewswire Inc.
TD Cowen Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price - MarketBeat
Elanco launches $25M VC program to invest in animal health innovation - Indianapolis Business Journal
Elanco Animal Health Incorporated Establishes Elanco Ventures Corporate Venture Capital Platform - marketscreener.com
Elanco plans VC platform to fast track animal health innovation - Feedstuffs
Elanco Animal Health Launches Venture Capital Platform - Intellectia AI
Elanco (ELAN) Launches Venture Capital Platform for Animal Healt - GuruFocus
Elanco bets $25 million on startup tech for animal health - Stock Titan
Elanco Animal Health Inc (ELAN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Elanco Animal Health Inc (ELAN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Elanco Animal Health Inc (ELAN) Institutional Confidence - TradingKey
Elanco Animal Health Inc (ELAN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Elanco Animal Health Inc (ELAN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Elanco Animal Health Inc (ELAN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
A Look at Elanco Animal Health Inc (ELAN) After 3.5% Decline -- GF Value $15.55 vs Price $23.39 - GuruFocus
ExodusPoint Capital Management LP Buys 491,617 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco (ELAN) CFO VanHimbergen receives deferred stock unit grant under deferral plan - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons receives deferred stock unit grant - Stock Titan
Deferred stock award to Elanco (NYSE: ELAN) executive disclosed - Stock Titan
Elanco Animal Health Inc (ELAN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Elanco CEO: Screwworm Easier To Manage Than Contain - marketscreener.com
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the Fir - GuruFocus
9 New 4-Star Stocks This Week - Morningstar
Elanco (ELAN) Introduces TruCan Ultra Lyme-L4 Vaccine for Dogs - GuruFocus
Elanco receives USDA approval for canine combination vaccine By Investing.com - Investing.com Canada
New low-volume dog vaccine targets Lyme and leptospirosis in a single shot - Stock Titan
Elanco Animal Health Inc (ELAN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Elanco Animal Health Incorporated $ELAN Position Reduced by Black Creek Investment Management Inc. - MarketBeat
Private Management Group Inc. Reduces Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Q1 earnings call highlights - MSN
Brandes Investment Partners LP Has $95.09 Million Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Inc (ELAN) Shares Surge 3.5% -- What GF Sco - GuruFocus
Norges Bank Makes New $32.42 Million Investment in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated $ELAN Shares Sold by Bank of New York Mellon Corp - MarketBeat
Elanco Animal Health (ELAN) Stock Analysis: A 26% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Clearbridge Investments LLC Has $128.37 Million Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Harvest Fund Management Co. Ltd Has $366,000 Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
TD Asset Management Inc Purchases 516,628 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Jim Cramer Recommends Elanco Over Zoetis - Insider Monkey
Is Elanco’s Big Rally Still Worth Watching After Its Sharp Climb? - Kalkine Media
Earnings call transcript: Elanco Animal Health Q1 2026 surpasses expectations with strong growth - Investing.com
Is It Too Late To Consider Elanco Animal Health (ELAN) After Its Strong 1 Year Rally? - Yahoo Finance
Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm - CSRwire
Elanco offers treatments for New World screwworm in U.S. livestock By Investing.com - Investing.com Canada
Elanco Animal HealthOffers Treatment Options For Livestock And Pets Against New World Screwworm - TradingView
Elanco Animal Health Incorporated $ELAN Shares Bought by Bowen Hanes & Co. Inc. - MarketBeat
Elanco Animal Health Inc (ELAN) Stock Up 4.0% but GF Value Says Overvalued -- GF Score: 66/100 - GuruFocus
Survey: Pet owners maintain health spending despite rising costs - PetfoodIndustry
Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick - Benzinga
U.S. pet owners cut dining out before pet care, Elanco finds - Stock Titan
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):